MedPath

Assessment the efficacy of atomoxetin(stramox) in autism spectrum disorders

Phase 2
Conditions
Autism spectrum disorders.
Childhood autism
F84.0, F84
Registration Number
IRCT2016022826802N1
Lead Sponsor
Vice chancellor for research of mashhad university of medical sciences
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
40
Inclusion Criteria

The inclusion criteria: Of all patients with ASD, ranging in age from 6 to 17 years; Parent's Consent; No obvious organic disease; The lack of other psychiatric disorders; Not taking other psychoactive medications other than risperidone; IQ higher than 50 on the basis of Weiland test
The exclusion criteria: In the absence of cooperation of parents after inclusion; the risk of any side effect or another disease that cause a problem in results.

Exclusion Criteria

Not provided

Study & Design

Study Type
interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Autism. Timepoint: Previous the syudy, 4 weeks after study, 8 weeks after study. Method of measurement: CARS test,CGI test.
Secondary Outcome Measures
NameTimeMethod
Drug's side effect. Timepoint: Previous the study, 4weeks after study, 8 weeks after study. Method of measurement: Check list.
© Copyright 2025. All Rights Reserved by MedPath